Simulations Plus, Inc.
Simulations Plus, Inc. (SLP) Stock Competitors & Peer Comparison
See (SLP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SLP | $14.91 | +5.22% | 301.3M | -4.78 | -$3.12 | N/A |
| BTSGU | $174.16 | +10.20% | 33.7B | N/A | N/A | N/A |
| VEEV | $171.60 | +10.02% | 28.2B | 31.55 | $5.44 | N/A |
| GEHC | $61.03 | +0.31% | 27.8B | 14.64 | $4.17 | +0.23% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $52.58 | +9.61% | 10.2B | 109.54 | $0.48 | N/A |
| TEM | $55.00 | -0.87% | 9.6B | -39.01 | -$1.41 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $82.40 | +0.45% | 7B | 33.48 | $2.46 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
SLP vs BTSGU Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BTSGU has a market cap of 33.7B. Regarding current trading prices, SLP is priced at $14.91, while BTSGU trades at $174.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BTSGU's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, SLP is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BTSGU's competition here
SLP vs VEEV Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, VEEV has a market cap of 28.2B. Regarding current trading prices, SLP is priced at $14.91, while VEEV trades at $171.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas VEEV's P/E ratio is 31.55. In terms of profitability, SLP's ROE is -0.49%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, SLP is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check VEEV's competition here
SLP vs GEHC Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, GEHC has a market cap of 27.8B. Regarding current trading prices, SLP is priced at $14.91, while GEHC trades at $61.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas GEHC's P/E ratio is 14.64. In terms of profitability, SLP's ROE is -0.49%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, SLP is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check GEHC's competition here
SLP vs GEHCV Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, SLP is priced at $14.91, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas GEHCV's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, SLP is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check GEHCV's competition here
SLP vs BTSG Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BTSG has a market cap of 10.2B. Regarding current trading prices, SLP is priced at $14.91, while BTSG trades at $52.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BTSG's P/E ratio is 109.54. In terms of profitability, SLP's ROE is -0.49%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, SLP is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BTSG's competition here
SLP vs TEM Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, TEM has a market cap of 9.6B. Regarding current trading prices, SLP is priced at $14.91, while TEM trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas TEM's P/E ratio is -39.01. In terms of profitability, SLP's ROE is -0.49%, compared to TEM's ROE of -0.60%. Regarding short-term risk, SLP is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check TEM's competition here
SLP vs SGFY Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, SLP is priced at $14.91, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SGFY's P/E ratio is 70.91. In terms of profitability, SLP's ROE is -0.49%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, SLP is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check SGFY's competition here
SLP vs HQY Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HQY has a market cap of 7B. Regarding current trading prices, SLP is priced at $14.91, while HQY trades at $82.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HQY's P/E ratio is 33.48. In terms of profitability, SLP's ROE is -0.49%, compared to HQY's ROE of +0.10%. Regarding short-term risk, SLP is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check HQY's competition here
SLP vs RCM Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, SLP is priced at $14.91, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas RCM's P/E ratio is -102.21. In terms of profitability, SLP's ROE is -0.49%, compared to RCM's ROE of +0.00%. Regarding short-term risk, SLP is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check RCM's competition here
SLP vs DOCS Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, DOCS has a market cap of 4.7B. Regarding current trading prices, SLP is priced at $14.91, while DOCS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas DOCS's P/E ratio is 21.00. In terms of profitability, SLP's ROE is -0.49%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, SLP is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check DOCS's competition here
SLP vs HNGE Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HNGE has a market cap of 3.6B. Regarding current trading prices, SLP is priced at $14.91, while HNGE trades at $45.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HNGE's P/E ratio is -5.85. In terms of profitability, SLP's ROE is -0.49%, compared to HNGE's ROE of -1.32%. Regarding short-term risk, SLP is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check HNGE's competition here
SLP vs ONEM Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, SLP is priced at $14.91, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ONEM's P/E ratio is -7.77. In terms of profitability, SLP's ROE is -0.49%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, SLP is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check ONEM's competition here
SLP vs PRVA Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, PRVA has a market cap of 3.1B. Regarding current trading prices, SLP is priced at $14.91, while PRVA trades at $24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas PRVA's P/E ratio is 138.06. In terms of profitability, SLP's ROE is -0.49%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, SLP is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check PRVA's competition here
SLP vs TXG Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, TXG has a market cap of 2.9B. Regarding current trading prices, SLP is priced at $14.91, while TXG trades at $22.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas TXG's P/E ratio is -64.09. In terms of profitability, SLP's ROE is -0.49%, compared to TXG's ROE of -0.06%. Regarding short-term risk, SLP is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check TXG's competition here
SLP vs HTFL Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, SLP is priced at $14.91, while HTFL trades at $28.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HTFL's P/E ratio is -9.04. In terms of profitability, SLP's ROE is -0.49%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, SLP is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check HTFL's competition here
SLP vs PINC Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, SLP is priced at $14.91, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas PINC's P/E ratio is 166.24. In terms of profitability, SLP's ROE is -0.49%, compared to PINC's ROE of -0.02%. Regarding short-term risk, SLP is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check PINC's competition here
SLP vs OMCL Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, OMCL has a market cap of 1.9B. Regarding current trading prices, SLP is priced at $14.91, while OMCL trades at $42.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas OMCL's P/E ratio is 97.27. In terms of profitability, SLP's ROE is -0.49%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, SLP is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check OMCL's competition here
SLP vs WGS Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, SLP is priced at $14.91, while WGS trades at $65.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas WGS's P/E ratio is -89.56. In terms of profitability, SLP's ROE is -0.49%, compared to WGS's ROE of -0.07%. Regarding short-term risk, SLP is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check WGS's competition here
SLP vs NXGN Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, SLP is priced at $14.91, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas NXGN's P/E ratio is -266.00. In terms of profitability, SLP's ROE is -0.49%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, SLP is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check NXGN's competition here
SLP vs PGNY Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, PGNY has a market cap of 1.5B. Regarding current trading prices, SLP is priced at $14.91, while PGNY trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas PGNY's P/E ratio is 28.62. In terms of profitability, SLP's ROE is -0.49%, compared to PGNY's ROE of +0.11%. Regarding short-term risk, SLP is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check PGNY's competition here
SLP vs AGTI Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, SLP is priced at $14.91, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas AGTI's P/E ratio is -71.79. In terms of profitability, SLP's ROE is -0.49%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, SLP is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check AGTI's competition here
SLP vs TDOC Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, SLP is priced at $14.91, while TDOC trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas TDOC's P/E ratio is -0.22. In terms of profitability, SLP's ROE is -0.49%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, SLP is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check TDOC's competition here
SLP vs CERT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CERT has a market cap of 946M. Regarding current trading prices, SLP is priced at $14.91, while CERT trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CERT's P/E ratio is -617.00. In terms of profitability, SLP's ROE is -0.49%, compared to CERT's ROE of -0.00%. Regarding short-term risk, SLP is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check CERT's competition here
SLP vs SDGR Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SDGR has a market cap of 925.8M. Regarding current trading prices, SLP is priced at $14.91, while SDGR trades at $12.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SDGR's P/E ratio is -8.79. In terms of profitability, SLP's ROE is -0.49%, compared to SDGR's ROE of -0.29%. Regarding short-term risk, SLP is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SDGR's competition here
SLP vs OMDA Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, OMDA has a market cap of 901M. Regarding current trading prices, SLP is priced at $14.91, while OMDA trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas OMDA's P/E ratio is -43.69. In terms of profitability, SLP's ROE is -0.49%, compared to OMDA's ROE of -0.07%. Regarding short-term risk, SLP is less volatile compared to OMDA. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check OMDA's competition here
SLP vs GDRX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, GDRX has a market cap of 873.9M. Regarding current trading prices, SLP is priced at $14.91, while GDRX trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas GDRX's P/E ratio is 28.33. In terms of profitability, SLP's ROE is -0.49%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, SLP is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check GDRX's competition here
SLP vs CCLDO Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, SLP is priced at $14.91, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CCLDO's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to CCLDO's ROE of +0.19%. Regarding short-term risk, SLP is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check CCLDO's competition here
SLP vs NUTX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, NUTX has a market cap of 831M. Regarding current trading prices, SLP is priced at $14.91, while NUTX trades at $139.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas NUTX's P/E ratio is 13.32. In terms of profitability, SLP's ROE is -0.49%, compared to NUTX's ROE of +0.29%. Regarding short-term risk, SLP is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check NUTX's competition here
SLP vs MPLN-WT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, SLP is priced at $14.91, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to MPLN-WT's ROE of +3.78%. Regarding short-term risk, SLP is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check MPLN-WT's competition here
SLP vs HSTM Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HSTM has a market cap of 607.2M. Regarding current trading prices, SLP is priced at $14.91, while HSTM trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HSTM's P/E ratio is 33.97. In terms of profitability, SLP's ROE is -0.49%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, SLP is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check HSTM's competition here
SLP vs PHR Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, PHR has a market cap of 587.9M. Regarding current trading prices, SLP is priced at $14.91, while PHR trades at $9.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas PHR's P/E ratio is 241.88. In terms of profitability, SLP's ROE is -0.49%, compared to PHR's ROE of +0.01%. Regarding short-term risk, SLP is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check PHR's competition here
SLP vs ACCD Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, SLP is priced at $14.91, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ACCD's P/E ratio is -3.08. In terms of profitability, SLP's ROE is -0.49%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, SLP is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check ACCD's competition here
SLP vs SHCR Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, SLP is priced at $14.91, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SHCR's P/E ratio is -3.76. In terms of profitability, SLP's ROE is -0.49%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, SLP is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check SHCR's competition here
SLP vs CTEV Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CTEV has a market cap of 420.6M. Regarding current trading prices, SLP is priced at $14.91, while CTEV trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CTEV's P/E ratio is -1.43. In terms of profitability, SLP's ROE is -0.49%, compared to CTEV's ROE of +3.78%. Regarding short-term risk, SLP is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check CTEV's competition here
SLP vs EVH Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, EVH has a market cap of 418.1M. Regarding current trading prices, SLP is priced at $14.91, while EVH trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas EVH's P/E ratio is -0.74. In terms of profitability, SLP's ROE is -0.49%, compared to EVH's ROE of -0.69%. Regarding short-term risk, SLP is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check EVH's competition here
SLP vs SLGC Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, SLP is priced at $14.91, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SLGC's P/E ratio is -3.04. In terms of profitability, SLP's ROE is -0.49%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, SLP is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SLGC's competition here
SLP vs SLGCW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, SLP is priced at $14.91, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, SLP's ROE is -0.49%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, SLP is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SLGCW's competition here
SLP vs SY Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SY has a market cap of 394.8M. Regarding current trading prices, SLP is priced at $14.91, while SY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SY's P/E ratio is -8.57. In terms of profitability, SLP's ROE is -0.49%, compared to SY's ROE of -0.14%. Regarding short-term risk, SLP is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SY's competition here
SLP vs NRC Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, NRC has a market cap of 392.4M. Regarding current trading prices, SLP is priced at $14.91, while NRC trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas NRC's P/E ratio is 44.64. In terms of profitability, SLP's ROE is -0.49%, compared to NRC's ROE of +0.57%. Regarding short-term risk, SLP is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check NRC's competition here
SLP vs TBRG Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, TBRG has a market cap of 386.8M. Regarding current trading prices, SLP is priced at $14.91, while TBRG trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas TBRG's P/E ratio is 88.93. In terms of profitability, SLP's ROE is -0.49%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, SLP is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check TBRG's competition here
SLP vs SOPH Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SOPH has a market cap of 381.3M. Regarding current trading prices, SLP is priced at $14.91, while SOPH trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SOPH's P/E ratio is -4.55. In terms of profitability, SLP's ROE is -0.49%, compared to SOPH's ROE of -1.17%. Regarding short-term risk, SLP is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check SOPH's competition here
SLP vs MPLN Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, SLP is priced at $14.91, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas MPLN's P/E ratio is -0.23. In terms of profitability, SLP's ROE is -0.49%, compared to MPLN's ROE of +3.78%. Regarding short-term risk, SLP is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check MPLN's competition here
SLP vs TRHC Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, SLP is priced at $14.91, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas TRHC's P/E ratio is -4.27. In terms of profitability, SLP's ROE is -0.49%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, SLP is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check TRHC's competition here
SLP vs CARL Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CARL has a market cap of 257.9M. Regarding current trading prices, SLP is priced at $14.91, while CARL trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CARL's P/E ratio is -4.47. In terms of profitability, SLP's ROE is -0.49%, compared to CARL's ROE of -2.64%. Regarding short-term risk, SLP is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check CARL's competition here
SLP vs SMFR Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, SLP is priced at $14.91, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SMFR's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to SMFR's ROE of -0.07%. Regarding short-term risk, SLP is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SMFR's competition here
SLP vs SPOK Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SPOK has a market cap of 218.4M. Regarding current trading prices, SLP is priced at $14.91, while SPOK trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SPOK's P/E ratio is 17.86. In terms of profitability, SLP's ROE is -0.49%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, SLP is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SPOK's competition here
SLP vs CPSI Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, SLP is priced at $14.91, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CPSI's P/E ratio is -183.80. In terms of profitability, SLP's ROE is -0.49%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, SLP is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check CPSI's competition here
SLP vs CCLD Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CCLD has a market cap of 127.1M. Regarding current trading prices, SLP is priced at $14.91, while CCLD trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CCLD's P/E ratio is 29.90. In terms of profitability, SLP's ROE is -0.49%, compared to CCLD's ROE of +0.19%. Regarding short-term risk, SLP is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check CCLD's competition here
SLP vs OPRX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, OPRX has a market cap of 125.7M. Regarding current trading prices, SLP is priced at $14.91, while OPRX trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas OPRX's P/E ratio is 24.81. In terms of profitability, SLP's ROE is -0.49%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, SLP is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check OPRX's competition here
SLP vs AUGX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, SLP is priced at $14.91, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas AUGX's P/E ratio is -4.99. In terms of profitability, SLP's ROE is -0.49%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, SLP is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check AUGX's competition here
SLP vs HCAT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HCAT has a market cap of 106.7M. Regarding current trading prices, SLP is priced at $14.91, while HCAT trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HCAT's P/E ratio is -0.57. In terms of profitability, SLP's ROE is -0.49%, compared to HCAT's ROE of -0.55%. Regarding short-term risk, SLP is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check HCAT's competition here
SLP vs DH Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, DH has a market cap of 102.8M. Regarding current trading prices, SLP is priced at $14.91, while DH trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas DH's P/E ratio is -0.76. In terms of profitability, SLP's ROE is -0.49%, compared to DH's ROE of -0.47%. Regarding short-term risk, SLP is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check DH's competition here
SLP vs AMWL Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, AMWL has a market cap of 101M. Regarding current trading prices, SLP is priced at $14.91, while AMWL trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas AMWL's P/E ratio is -1.02. In terms of profitability, SLP's ROE is -0.49%, compared to AMWL's ROE of -0.36%. Regarding short-term risk, SLP is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check AMWL's competition here
SLP vs FORA Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, FORA has a market cap of 67.1M. Regarding current trading prices, SLP is priced at $14.91, while FORA trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas FORA's P/E ratio is -23.89. In terms of profitability, SLP's ROE is -0.49%, compared to FORA's ROE of -0.09%. Regarding short-term risk, SLP is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check FORA's competition here
SLP vs CCLDP Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, SLP is priced at $14.91, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CCLDP's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to CCLDP's ROE of +0.19%. Regarding short-term risk, SLP is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check CCLDP's competition here
SLP vs SNCE Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, SLP is priced at $14.91, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SNCE's P/E ratio is -0.27. In terms of profitability, SLP's ROE is -0.49%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, SLP is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check SNCE's competition here
SLP vs AKLI Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, SLP is priced at $14.91, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas AKLI's P/E ratio is -0.71. In terms of profitability, SLP's ROE is -0.49%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, SLP is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check AKLI's competition here
SLP vs SHLT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, SLP is priced at $14.91, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SHLT's P/E ratio is -3.87. In terms of profitability, SLP's ROE is -0.49%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, SLP is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check SHLT's competition here
SLP vs ONMD Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ONMD has a market cap of 32.6M. Regarding current trading prices, SLP is priced at $14.91, while ONMD trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ONMD's P/E ratio is -16.59. In terms of profitability, SLP's ROE is -0.49%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, SLP is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check ONMD's competition here
SLP vs SHCRW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, SLP is priced at $14.91, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, SLP's ROE is -0.49%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, SLP is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check SHCRW's competition here
SLP vs BEAT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BEAT has a market cap of 30.4M. Regarding current trading prices, SLP is priced at $14.91, while BEAT trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BEAT's P/E ratio is -1.42. In terms of profitability, SLP's ROE is -0.49%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, SLP is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BEAT's competition here
SLP vs EUDA Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, EUDA has a market cap of 29.5M. Regarding current trading prices, SLP is priced at $14.91, while EUDA trades at $15.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas EUDA's P/E ratio is 38.97. In terms of profitability, SLP's ROE is -0.49%, compared to EUDA's ROE of +0.14%. Regarding short-term risk, SLP is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check EUDA's competition here
SLP vs STRM Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, SLP is priced at $14.91, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas STRM's P/E ratio is -2.40. In terms of profitability, SLP's ROE is -0.49%, compared to STRM's ROE of -0.32%. Regarding short-term risk, SLP is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check STRM's competition here
SLP vs RNLX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, SLP is priced at $14.91, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas RNLX's P/E ratio is -0.33. In terms of profitability, SLP's ROE is -0.49%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, SLP is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check RNLX's competition here
SLP vs LIFW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, SLP is priced at $14.91, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas LIFW's P/E ratio is -0.02. In terms of profitability, SLP's ROE is -0.49%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, SLP is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check LIFW's competition here
SLP vs BBLN Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, SLP is priced at $14.91, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BBLN's P/E ratio is -0.04. In terms of profitability, SLP's ROE is -0.49%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, SLP is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BBLN's competition here
SLP vs ETAO Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, SLP is priced at $14.91, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ETAO's P/E ratio is -0.01. In terms of profitability, SLP's ROE is -0.49%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, SLP is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check ETAO's competition here
SLP vs BFRG Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BFRG has a market cap of 7.4M. Regarding current trading prices, SLP is priced at $14.91, while BFRG trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BFRG's P/E ratio is -1.11. In terms of profitability, SLP's ROE is -0.49%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, SLP is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BFRG's competition here
SLP vs HLTH Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, SLP is priced at $14.91, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HLTH's P/E ratio is -0.02. In terms of profitability, SLP's ROE is -0.49%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, SLP is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check HLTH's competition here
SLP vs ZCMD Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ZCMD has a market cap of 6.9M. Regarding current trading prices, SLP is priced at $14.91, while ZCMD trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ZCMD's P/E ratio is -1.15. In terms of profitability, SLP's ROE is -0.49%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, SLP is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check ZCMD's competition here
SLP vs SCNX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, SCNX has a market cap of 6.2M. Regarding current trading prices, SLP is priced at $14.91, while SCNX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas SCNX's P/E ratio is -0.15. In terms of profitability, SLP's ROE is -0.49%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, SLP is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check SCNX's competition here
SLP vs UPH-WT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, SLP is priced at $14.91, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, SLP is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check UPH-WT's competition here
SLP vs UPH Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, SLP is priced at $14.91, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas UPH's P/E ratio is -0.07. In terms of profitability, SLP's ROE is -0.49%, compared to UPH's ROE of -1.05%. Regarding short-term risk, SLP is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check UPH's competition here
SLP vs PEARW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, SLP is priced at $14.91, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas PEARW's P/E ratio is -0.00. In terms of profitability, SLP's ROE is -0.49%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, SLP is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check PEARW's competition here
SLP vs PEAR Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, SLP is priced at $14.91, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas PEAR's P/E ratio is -0.08. In terms of profitability, SLP's ROE is -0.49%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, SLP is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check PEAR's competition here
SLP vs BFRGW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BFRGW has a market cap of 3.3M. Regarding current trading prices, SLP is priced at $14.91, while BFRGW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BFRGW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, SLP is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BFRGW's competition here
SLP vs BEATW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, BEATW has a market cap of 3.2M. Regarding current trading prices, SLP is priced at $14.91, while BEATW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas BEATW's P/E ratio is -0.19. In terms of profitability, SLP's ROE is -0.49%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, SLP is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check BEATW's competition here
SLP vs MGRX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, MGRX has a market cap of 3.2M. Regarding current trading prices, SLP is priced at $14.91, while MGRX trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas MGRX's P/E ratio is -0.15. In terms of profitability, SLP's ROE is -0.49%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, SLP is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check MGRX's competition here
SLP vs VSEE Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, VSEE has a market cap of 3.1M. Regarding current trading prices, SLP is priced at $14.91, while VSEE trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas VSEE's P/E ratio is -0.26. In terms of profitability, SLP's ROE is -0.49%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, SLP is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check VSEE's competition here
SLP vs HCTI Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, HCTI has a market cap of 2.7M. Regarding current trading prices, SLP is priced at $14.91, while HCTI trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas HCTI's P/E ratio is -0.02. In terms of profitability, SLP's ROE is -0.49%, compared to HCTI's ROE of -1.01%. Regarding short-term risk, SLP is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check HCTI's competition here
SLP vs OTRK Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, SLP is priced at $14.91, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas OTRK's P/E ratio is -0.02. In terms of profitability, SLP's ROE is -0.49%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, SLP is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check OTRK's competition here
SLP vs ACON Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ACON has a market cap of 1.8M. Regarding current trading prices, SLP is priced at $14.91, while ACON trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ACON's P/E ratio is -0.25. In terms of profitability, SLP's ROE is -0.49%, compared to ACON's ROE of -0.00%. Regarding short-term risk, SLP is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check ACON's competition here
SLP vs CMAX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, SLP is priced at $14.91, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CMAX's P/E ratio is -0.00. In terms of profitability, SLP's ROE is -0.49%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, SLP is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check CMAX's competition here
SLP vs VSEEW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, VSEEW has a market cap of 1.6M. Regarding current trading prices, SLP is priced at $14.91, while VSEEW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas VSEEW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, SLP is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check VSEEW's competition here
SLP vs EUDAW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, EUDAW has a market cap of 1.3M. Regarding current trading prices, SLP is priced at $14.91, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas EUDAW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to EUDAW's ROE of +0.14%. Regarding short-term risk, SLP is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check EUDAW's competition here
SLP vs LIFWZ Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, SLP is priced at $14.91, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, SLP is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check LIFWZ's competition here
SLP vs MSPR Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, MSPR has a market cap of 551K. Regarding current trading prices, SLP is priced at $14.91, while MSPR trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas MSPR's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, SLP is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check MSPR's competition here
SLP vs MSPRZ Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, SLP is priced at $14.91, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, SLP is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check MSPRZ's competition here
SLP vs WORX Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, SLP is priced at $14.91, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas WORX's P/E ratio is -0.12. In terms of profitability, SLP's ROE is -0.49%, compared to WORX's ROE of -0.73%. Regarding short-term risk, SLP is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check WORX's competition here
SLP vs WGSWW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, WGSWW has a market cap of 163.3K. Regarding current trading prices, SLP is priced at $14.91, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas WGSWW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to WGSWW's ROE of -0.07%. Regarding short-term risk, SLP is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check WGSWW's competition here
SLP vs KERNW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, SLP is priced at $14.91, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas KERNW's P/E ratio is -0.00. In terms of profitability, SLP's ROE is -0.49%, compared to KERNW's ROE of -0.02%. Regarding short-term risk, SLP is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check KERNW's competition here
SLP vs KERN Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, SLP is priced at $14.91, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas KERN's P/E ratio is -0.01. In terms of profitability, SLP's ROE is -0.49%, compared to KERN's ROE of -0.02%. Regarding short-term risk, SLP is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check KERN's competition here
SLP vs LIFWW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, SLP is priced at $14.91, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas LIFWW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, SLP is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check LIFWW's competition here
SLP vs OTRKP Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, SLP is priced at $14.91, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, SLP's ROE is -0.49%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, SLP is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check OTRKP's competition here
SLP vs CMAXW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, SLP is priced at $14.91, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas CMAXW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, SLP is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check CMAXW's competition here
SLP vs ACONW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ACONW has a market cap of 18.5K. Regarding current trading prices, SLP is priced at $14.91, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ACONW's P/E ratio is -0.01. In terms of profitability, SLP's ROE is -0.49%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, SLP is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check ACONW's competition here
SLP vs ICCT Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, SLP is priced at $14.91, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas ICCT's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, SLP is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for SLP.Check ICCT's competition here
SLP vs MSPRW Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, MSPRW has a market cap of 4.1K. Regarding current trading prices, SLP is priced at $14.91, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas MSPRW's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, SLP is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check MSPRW's competition here
SLP vs FOXO Comparison May 2026
SLP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLP stands at 301.3M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, SLP is priced at $14.91, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLP currently has a P/E ratio of -4.78, whereas FOXO's P/E ratio is N/A. In terms of profitability, SLP's ROE is -0.49%, compared to FOXO's ROE of -0.91%. Regarding short-term risk, SLP is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for SLP.Check FOXO's competition here